11β-HSD1-IN-11

TargetMol
Product Code: TAR-T60149
Supplier: TargetMol
CodeSizePrice
TAR-T60149-1mg1mg£227.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T60149-1mL1 mL * 10 mM (in DMSO)£426.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T60149-5mg5mg£430.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T60149-10mg10mg£600.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T60149-25mg25mg£863.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T60149-50mg50mg£1,179.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T60149-100mg100mg£1,589.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T60149-500mg500mg£3,115.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C

Images

1 / 1

Further Information

Bioactivity:
11β-HSd1-in-11 is a potent and competitive inhibitor of 11-β-hydroxysteroid dehydrogenase 1 (11β-HSD1) IN rats and humans with IC50 values of 0.34 uM and 0.13 uM, respectively. 11β-Hsvd1-in-11 is a compound used as a chemical compound. 11β-HSD1-IN-11 is a hormone involved in regulating various physiological processes, such as metabolism, inflammation, and stress responses. 11β-Hd1-in-11 is a potential compound for the treatment of metabolic disorders, obesity, and certain inflammatory conditions.
CAS:
859721-81-6
Molecular Weight:
328.31
Pathway:
Metabolism
Purity:
0.9942
SMILES:
O=C(C1=CC=C(C=C1)C(F)(F)F)CS(=O)(=O)C=2C=CC=CC2
Target:
Dehydrogenase

References

Naredo-Gonzalez G, et al. Non-invasive in vivo assessment of 11?-hydroxysteroid dehydrogenase type 1 activity by 19F-Magnetic Resonance Spectroscopy. Sci Rep. 2022 Sep 29;12(1):16268.